NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.82 -4.78%

-$0.07 today

Market cap
$94.78M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.86M

Average 0.90M

Returns on capital

NovaBridge Biosciences management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-20.0%

avg -133.6%

ROIC

-40.2%

avg -59.2%

ROA

-17.8%

avg -97.1%

Analysis

ROA is currently the strongest return metric at -17.8% versus its period average of -97.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Cong Xu

Executive VP and Head of R&D Center of Excellence—41——

Srishti Gupta

Chief Executive Officer & Director—503.00M5.99%

Phillip Dennis

Chief Medical Officer—63——

Mark Hagler

President & Chief Commercial Officer————

Ming Lei

Chief Financial Officer—29——

Sean Wuxiong Cao

Chief Business Development Officer & Director—59266.47K0.53%

Tyler Ehler

Senior Director of Investor Relations————

Wei Fu

Executive Chairman—44725.14K1.45%

Liwei Lin

General Counsel & Board Secretary—38——

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 9, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$577,300.00

Sells

7

$154,272.95

Net Transaction Value

+$423,027.05

Net buying

Most Active

Xu Cong Claire

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 18, 26

Dennis Phillip Andrew

Direct

Sell$5.8K
Sep 9, 26

Cao Sean Wuxiong

Direct

Sell$79.9K
Aug 31, 26

Xu Cong Claire

Direct

Sell$2.6K
Jul 6, 26

Xu Cong Claire

Direct

Sell$4K
Jun 18, 26

Dennis Phillip Andrew

Direct

Sell$5.6K
Jun 1, 26

Xu Cong Claire

Direct

Sell$13.8K
May 14, 26

Cao Sean Wuxiong

Direct

Sell$42.6K
Apr 24, 26

Hagler Mark Arnold

Direct

Buy$577.3K

Summary

Insiders reported 1 buys worth $577,300.00 and 7 sells worth $154,272.95 over the last 12 months. That adds up to net buying of $423,027.05. Xu Cong Claire was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does NovaBridge Biosciences compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NBP's management, answered from reported figures.

Who manages NBP?

NovaBridge Biosciences (NBP) lists 9 active executives. The top listed executive is Cong Xu, Executive VP and Head of R&D Center of Excellence.

Are NBP insiders buying or selling?

Recent insider activity shows net buying of $13.50M.